Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Sarepta Therapeutics (SRPT)

Sarepta Therapeutics (SRPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,947,961
  • Shares Outstanding, K 94,524
  • Annual Sales, $ 1,243 M
  • Annual Income, $ -535,980 K
  • 60-Month Beta 0.89
  • Price/Sales 11.10
  • Price/Cash Flow N/A
  • Price/Book 14.52
Trade SRPT with:

Options Overview Details

View History
  • Implied Volatility 49.10% ( -0.65%)
  • Historical Volatility 82.06%
  • IV Percentile 26%
  • IV Rank 6.19%
  • IV High 247.47% on 10/20/23
  • IV Low 36.02% on 12/01/23
  • Put/Call Vol Ratio 0.77
  • Today's Volume 4,512
  • Volume Avg (30-Day) 1,759
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 54,140
  • Open Int (30-Day) 70,461

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.00
  • Number of Estimates 7
  • High Estimate 0.45
  • Low Estimate -0.12
  • Prior Year -0.27
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
143.31 +0.65%
on 07/26/24
162.95 -11.48%
on 07/01/24
-12.67 (-8.07%)
since 06/26/24
3-Month
109.91 +31.23%
on 05/28/24
173.25 -16.74%
on 06/21/24
+15.47 (+12.01%)
since 04/26/24
52-Week
55.25 +161.07%
on 10/31/23
173.25 -16.74%
on 06/21/24
+40.11 (+38.52%)
since 07/26/23

Most Recent Stories

More News
After a Big Win, Is Sarepta Therapeutics Stock a Buy?

One key issue remains unresolved, and it could be a significant one.

SRPT : 144.24 (-2.25%)
Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?

The label expansion paves the way for much more revenue growth for Sarepta in the years ahead.

SRPT : 144.24 (-2.25%)
1 Soaring Growth Stock to Buy and Hold for 10 Years

Let's look beyond the biotech's performance this year.

SRPT : 144.24 (-2.25%)
Stocks Under Pressure from Higher Bond Yields

The S&P 500 Index ($SPX ) (SPY ) today is down -0.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.16%. Stock indexes today are mildly...

$SPX : 5,459.10 (+1.11%)
SPY : 544.44 (+1.12%)
$DOWI : 40,589.34 (+1.64%)
DIA : 405.97 (+1.62%)
$IUXX : 19,023.66 (+1.03%)
QQQ : 462.97 (+1.03%)
ZNU24 : 111-065s (+0.37%)
FDX : 300.14 (+0.52%)
UPS : 128.83 (+1.38%)
ODFL : 202.93 (-1.35%)
JBHT : 171.54 (+0.45%)
APTV : 68.74 (+1.34%)
Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.

One company's negative results can increase scrutiny of another's work.

PFE : 30.77 (+3.39%)
SRPT : 144.24 (-2.25%)
Hawkish Comments from Fed Governor Bowman Weigh on Stocks

The S&P 500 Index ($SPX ) (SPY ) today is down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.33%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.15%. Stock indexes today are mildly...

$SPX : 5,459.10 (+1.11%)
SPY : 544.44 (+1.12%)
$DOWI : 40,589.34 (+1.64%)
DIA : 405.97 (+1.62%)
$IUXX : 19,023.66 (+1.03%)
QQQ : 462.97 (+1.03%)
ZNU24 : 111-065s (+0.37%)
APTV : 68.74 (+1.34%)
GIS : 66.32 (+0.74%)
LUV : 27.23 (-3.03%)
UAL : 47.37 (+1.39%)
DAL : 44.13 (+1.52%)
Stock market today: Wall Street coasts to the close of another winning week as Nvidia cools again

U.S. stocks coasted to the close of their latest winning week, as Nvidia’s stock continued to cool from its startling, supernova run

KMX : 83.02 (+1.80%)
$SPX : 5,459.10 (+1.11%)
$DOWI : 40,589.34 (+1.64%)
$IUXX : 19,023.66 (+1.03%)
SPGI : 489.82 (+1.34%)
SWBI : 16.11 (+2.35%)
SRPT : 144.24 (-2.25%)
MSFT : 425.27 (+1.64%)
Sarepta Therapeutics, Ryan Specialty rise; Autodesk, Trump Media fall, Friday, 6/21/2024

Stocks that traded heavily or had substantial price changes on Friday: Sarepta Therapeutics, Ryan Specialty rise; Autodesk, Trump Media fall

HTZ : 4.07 (+5.17%)
FDS : 415.33 (+0.89%)
ASAN : 15.37 (+1.92%)
DJT : 31.45 (+1.29%)
RYAN : 60.61 (+2.57%)
SRPT : 144.24 (-2.25%)
Stocks Settle Mostly Lower on Chip Stock Weakness

The S&P 500 Index ($SPX ) (SPY ) Friday closed down -0.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.26%. Stock indexes...

$SPX : 5,459.10 (+1.11%)
SPY : 544.44 (+1.12%)
$DOWI : 40,589.34 (+1.64%)
DIA : 405.97 (+1.62%)
$IUXX : 19,023.66 (+1.03%)
QQQ : 462.97 (+1.03%)
ZNU24 : 111-065s (+0.37%)
AVGO : 151.63 (+1.59%)
NVDA : 113.06 (+0.69%)
AMAT : 206.47 (+2.05%)
QCOM : 180.05 (+2.66%)
LRCX : 894.64 (+1.19%)
Quiver's Morning Markets Wrap

Nvidia (NVDA) led a selloff in chipmakers, causing stocks to waver as Wall Street prepared for a significant options expiry. Known as "triple witching," this quarterly event involves the expiration of...

NVDA : 113.06 (+0.69%)
DELL : 113.56 (+1.91%)
SMCI : 712.19 (+2.38%)
MSFT : 425.27 (+1.64%)
AAL : 10.62 (+0.19%)
SRPT : 144.24 (-2.25%)
SPY : 544.44 (+1.12%)
QQQ : 462.97 (+1.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company that focuses on the discovery and development of RNA-based therapeutics targeting rare and infectious diseases. It concentrates on the development of exon-skipping drug candidates targeting Duchenne muscular dystrophy (DMD), a...

See More

Key Turning Points

3rd Resistance Point 151.95
2nd Resistance Point 150.03
1st Resistance Point 147.14
Last Price 144.24
1st Support Level 142.33
2nd Support Level 140.41
3rd Support Level 137.52

See More

52-Week High 173.25
Last Price 144.24
Fibonacci 61.8% 128.17
Fibonacci 50% 114.25
Fibonacci 38.2% 100.33
52-Week Low 55.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar